FAQ/Help |
Calendar |
Search |
Today's Posts |
|
12-15-2008, 08:02 PM | #1 | |||
|
||||
Member
|
From another article:
Finding genetic markers for the placebo effect could raise ethical questions about how companies design their clinical trials, Furmark says. For example, "it could be tempting to screen all individuals and ... select only those with [the] nonresponsive phenotype [for the trial]." Why is that an ethical question? It would be wonderful if one could exclude those that might exhibit a strong placebo effect from the trial. How is that possibly unethical? http://sciencenow.sciencemag.org/cgi...ll/2008/1202/1 |
|||
Reply With Quote |
12-16-2008, 12:50 PM | #2 | ||
|
|||
In Remembrance
|
Quote:
I'm still somewhat in a fog today so if the logic is off here I'm sorry. But would it be better to just factor in the placebo genes [somehow] and still let those prone to placebo effect have a shot at the treatment? I'm not sure if that even makes sense, but wouldn't it be unethical to eliminate those with the genes from getting a potentially life saving treatment in time? Is that what they are saying? paula
__________________
paula "Time is not neutral for those who have pd or for those who will get it." |
||
Reply With Quote |
12-16-2008, 07:40 PM | #3 | |||
|
||||
Member
|
Hi Paula,
I would expect them to get the drug when and if it is approved, of course. I'm only talking about the trial. I suppose that one could include them in the trial to see if those genetic differences have the same effect re: placebo effect. But, I would not want their results to count when the effectiveness of the drug is analyzed. In other words, let them join the trial, but don't let their genes screw up the results of the trial. |
|||
Reply With Quote |
"Thanks for this!" says: | paula_w (12-16-2008) |
Reply |
|
|
Similar Threads | ||||
Thread | Forum | |||
Placebo effect may influence depression treatment | Parkinson's Disease | |||
Sham Surgery and the Placebo Effect | Parkinson's Disease Clinical Trials |